Peppercorn, Katie, Edgar, Christina D, Al Momani, Suzan et al. · Methods in molecular biology (Clifton, N.J.) · 2025 · DOI
This study describes a technique called RRBS that examines how chemical tags on our DNA (called methylation) are different in ME/CFS patients compared to healthy people. These tags act like switches that turn genes on or off, and abnormal patterns might help explain why ME/CFS causes such severe symptoms. The researchers show how this method can be used to identify patterns that could eventually lead to better diagnostic tests or ways to track how the illness changes over time.
Identifying biomarkers for ME/CFS is critically important since the condition currently lacks objective diagnostic tests, forcing patients to rely on clinical criteria alone. This DNA methylation approach could eventually enable early diagnosis, disease monitoring, and assessment of treatment response—potentially transforming how ME/CFS is clinically managed. Understanding the epigenetic basis of ME/CFS may also reveal key biological mechanisms underlying the illness, particularly its post-viral origins.
This methodological study does not prove that specific methylation changes cause ME/CFS symptoms or that these epigenetic patterns are disease-specific. The paper does not present clinical validation data showing that methylation biomarkers can reliably diagnose ME/CFS in independent patient populations. It also does not establish whether methylation changes are primary drivers of pathology or secondary consequences of the disease process.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.